Merck to initiate Phase II Keytruda trials on back of new data
This article was originally published in Scrip
Executive Summary
Merck's anti-PD-1 drug Keytruda (pembrolizumab) shows promise in both gastric and bladder cancers, with overall response rates 31% and 24% respectively, according to new data released at ESMO this weekend.